BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9186779)

  • 1. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
    Richardson DR
    Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
    Richardson DR; Tran EH; Ponka P
    Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR; Milnes K
    Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
    Becker E; Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
    Buss JL; Arduini E; Ponka P
    Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
    Ponka P; Grady RW; Wilczynska A; Schulman HM
    Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR; Ponka P
    J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
    Baker E; Vitolo ML; Webb J
    Biochem Pharmacol; 1985 Sep; 34(17):3011-7. PubMed ID: 4038321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe.
    Huang AR; Ponka P
    Biochim Biophys Acta; 1983 Jun; 757(3):306-15. PubMed ID: 6849979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
    Buss JL; Arduini E; Shephard KC; Ponka P
    Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
    Ponka P; Schulman HM; Wilczynska A
    Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
    Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
    Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ceruloplasmin and ascorbate in cellular iron release.
    Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):454-65. PubMed ID: 10560938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
    Ponka P; Richardson DR; Edward JT; Chubb FL
    Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
    Cikrt M; Ponka P; Necas E; Neuwirt J
    Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
    Bláha K; Cikrt M; Nerudová J; Ponka HF
    Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chelators on iron uptake and release by the brain in the rat.
    Crowe A; Morgan EH
    Neurochem Res; 1994 Jan; 19(1):71-6. PubMed ID: 8139766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.